II. Indications (Part of combination protocols)

III. Mechanism

  1. Second-generation platinum based Antineoplastic Agent
    1. More stable and less toxic than its parent drug Cisplatin
  2. Components
    1. Platinum atom
    2. 1,2-diaminocyclohexane (DACH)
      1. Decreases Alkylating Agent resistance
    3. Oxalate Ligand (displaced, "leaving group")
  3. Activated (on displacement of the oxalate leaving group) as reactive platinum complexes
    1. Binds DNA (e.g. GC rich regions)
    2. Results in DNA cross-links
    3. Results in cell growth inhibition, apoptosis and cell death

IV. Dosing

  1. See other references for disease specific dosing protocols

V. Adverse Effects

  1. Anaphylaxis
    1. May occur within minutes of infusion
    2. Acute Laryngospasm may also occur
  2. Bronchiolitis Obliterans Organizing Pneumonia (rare)
  3. Cardiovascular Toxicity
  4. Impaired future fertility
  5. Myelosuppression (Bone Marrow suppression)
  6. Neuropathy
    1. Exposure to cold after infusion may worsen acute neurotoxicity
  7. Neutropenia (severe)
  8. Posterior Reversible Encephalopathy Syndrome (Rare)
  9. Pulmonary Fibrosis
  10. Rhabdomyolysis
  11. Transient Vision Loss

VI. Safety

  1. Avoid in Lactation
  2. Pregnancy Category D
    1. Avoid in Pregnancy (all trimesters)
    2. Use reliable Contraception
  3. Monitoring
    1. Complete Blood Count
    2. Renal Function tests

VII. Efficacy

  1. More effective than Cisplatin in advanced Colorectal Cancer

Images: Related links to external sites (from Bing)

Related Studies

Ontology: oxaliplatin (C0069717)

Definition (NCI) An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)
Definition (NCI_NCI-GLOSS) A drug used with other drugs to treat colorectal cancer that is advanced or has come back. It is also being studied in the treatment of other types of cancer. Eloxatin attaches to DNA in cells and may kill cancer cells. It is a type of platinum compound.
Definition (PDQ) An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42374&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42374&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1181" NCI Thesaurus)
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C030110
SnomedCT 327032007, 395814003
LNC LP171626-7
English 1,2-diaminocyclohexane platinum oxalate, 1,2-diamminocyclohexane(trans-1)oxolatoplatinum(II), oxalato-(1,2-cyclohexanediamine)platinum II, platinum(II)-1,2-cyclohexanediamine oxalate, [(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum, oxalato (1R,2R-cyclohexanediamine)platinum(II), oxalato (trans-l-1,2-diaminocyclohexane)platinum(II), trans-l DACH oxalatoplatinum, trans-l diaminocyclohexane oxalatoplatinum, Diaminocyclohexane Oxalatoplatinum, Oxalatoplatin, Oxalatoplatinum, oxaliplatin, oxaliplatin (medication), OXALIPLATIN, oxaliplatin [Chemical/Ingredient], L-OHP cpd, oxaliplatine, 1-OHP, Oxaliplatin (product), Oxaliplatin (substance), Oxaliplatin, L-OHP
Spanish oxaliplatino (producto), oxaliplatino (sustancia), oxaliplatino